Nivolumab-related pancreatitis with autoimmune pancreatitis-like imaging features

A 70-year-old female with stage IV renal cell carcinoma was treated with nivolumab, an anti-programmed cell death protein 1 antibody. After 6 months of treatment, serum amylase and lipase levels were elevated (547 and 1830 U/L). Fat-suppressed T2-weighted abdominal magnetic resonance imaging demonstrated diffuse enlargement of the whole pancreas (Fig. 1a,b). Diffusion-weighted magnetic resonance imaging also showed restricted diffusion with high...